Edoxaban tosylate - Generic Drug Details

What are the generic drug sources for edoxaban tosylate and what is the scope of freedom to operate?

Edoxaban tosylate is the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Edoxaban tosylate has one hundred and one patent family members in thirty-four countries.

There are four drug master file entries for edoxaban tosylate. One supplier is listed for this compound.

Summary for edoxaban tosylate

International Patents:	101
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for edoxaban tosylate
What excipients (inactive ingredients) are in edoxaban tosylate?	edoxaban tosylate excipients list
DailyMed Link:	edoxaban tosylate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for edoxaban tosylate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for edoxaban tosylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo Inc.	Phase 2
Daiichi Sankyo, Inc.	Phase 2
Daiichi Sankyo Inc.	Phase 3

See all edoxaban tosylate clinical trials

Pharmacology for edoxaban tosylate

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for edoxaban tosylate

B01AF	Direct factor Xa inhibitors
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for EDOXABAN TOSYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAVAYSA	Tablets	edoxaban tosylate	15 mg, 30 mg and 60 mg	206316	1	2019-01-28

US Patents and Regulatory Information for edoxaban tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes				Y
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No				Y
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes			Y
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-001	Jan 8, 2015		RX	Yes	No

International Patents for edoxaban tosylate

Country	Patent Number	Title	Estimated Expiration
South Korea	100863113
Norway	327003
Singapore	179497	PHARMACEUTICAL COMPOSITION
Russian Federation	2009139917	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
European Patent Office	2140867
World Intellectual Property Organization (WIPO)	03000680

Supplementary Protection Certificates for edoxaban tosylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1405852	C01405852/01	Switzerland		PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015
1405852	122015000077	Germany		PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
2140867	PA2018005	Lithuania		PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
1405852	CR 2015 00052	Denmark		PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
1405852	132016000024022	Italy		PRODUCT NAME: EDOXABAN, UN SUO SALE, UN SUO SOLVATO O UN SUO N-OSSIDO, IN PARTICOLARE EDOXABAN TOSILATO(LIXIANA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/993/001-028, 20150623
2140867	292 50001-2018	Slovakia		PRODUCT NAME: EDOXABAN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/993 20150623

Market Dynamics and Financial Trajectory of Edoxaban Tosylate

Last updated: March 4, 2026

What is Edoxaban Tosylate?

Edoxaban Tosylate is an oral, direct factor Xa inhibitor used to prevent and treat blood clotting disorders. Approved by the FDA in 2015, it is marketed under the brand name Savaysa outside the U.S. and as Lixiana in Japan. It is primarily indicated for non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), and pulmonary embolism (PE).

Market Size and Growth Drivers

Global Market Valuation

• Estimated worth in 2022: approximately $4.2 billion
• Projected CAGR (2022–2027): 8.7%
• 2027 forecast: $7.4 billion (by analyst estimates)

Key Market Drivers

• Increasing prevalence of atrial fibrillation (AF) and venous thromboembolism (VTE)
• Rising geriatric population susceptible to clotting disorders
• Growing adoption of oral anticoagulants over injectable therapies
• Expanded indications based on clinical trial data
• Competitive positioning against warfarin, dabigatran, rivaroxaban, and apixaban

Regional Market Breakdown

• North America: 45% share; driven by high AF prevalence and favorable reimbursement policies
• Europe: 25%, with growth fueled by aging populations
• Asia-Pacific: 20%; rapid market expansion due to increased healthcare access
• Rest of the world: 10%; limited by regulatory delays and limited healthcare infrastructure

Competitive Landscape

Key Players

Company	Drug Name	Market Share (2022)	Key Strengths
Daiichi Sankyo	Edoxaban (Lixiana/Savaysa)	58%	First-to-market; established distribution network
Other competitors	Rivaroxaban, Apixaban, Dabigatran	42%	Strong brand recognition; diverse indications

Patent and Patent Expirations

• Edoxaban patent: expiration in 2025 (U.S. and EU)
• Patent protections influence market exclusivity, with generic competition expected thereafter

Regulatory and Reimbursement Environment

• FDA approval in 2015; NORDIC and other jurisdictions followed
• Reimbursement policies favor oral anticoagulants for NVAF and VTE
• Off-label use in prophylaxis of DVT post-surgery extends market potential
• Pending regulatory reviews for additional indications (e.g., stroke prevention in mechanical heart valves)

Revenue Trends and Future Outlook

Historical Revenue Data

Year	Revenue (USD millions)	Notes
2018	245	Post-approval market penetration
2019	312	Growing prescription volume
2020	385	Pandemic impact; increased anticoagulant use
2021	423	Expansion into new indications
2022	440	Market stabilization, incremental growth

Future Revenue Projections

• Estimated to reach approximately $750 million by 2027
• Growth driven by expanded licensed indications and increased adoption in emerging markets
• Patent expiry in 2025 potentially impacts revenue due to generic entry

Challenges and Risks

• Patent expiry risks leading to price erosion
• Competition from alternative anticoagulants, especially Rivaroxaban and Apixaban
• Safety concerns such as bleeding risk complicate physician prescribing patterns
• Regulatory delays or withdrawal of approval for certain indications

Key Takeaways

• Edoxaban Tosylate operates in a competitive, rapidly growing market driven by aging populations and increasing thromboembolic disease prevalence.
• The drug's revenue trajectory benefits from early market positioning and expanded indications but faces challenges from patent expiration and competitors.
• Regional disparities influence market dynamics, with North America and Europe being primary revenue sources.
• The expiration of patents around 2025 signals potential revenue decline unless offset by new indications or formulations.
• Continued market growth relies on clinical evidence, favorable reimbursement policies, and expansion into emerging markets.

FAQs

1. When will generic Edoxaban Tosylate enter the market?
Patent protection is expected to expire around 2025, after which generic versions are likely to become available, potentially reducing brand-name drug revenues.

2. How does Edoxaban compare to other factor Xa inhibitors?
Edoxaban has similar efficacy to rivaroxaban and apixaban but is distinguished by its dosing schedule and specific indication approvals. Market share reflects early entry and established distribution.

3. What new indications are in development for Edoxaban?
Research continues into stroke prevention in mechanical heart valves and extended prophylaxis post-surgery, but no regulatory approvals are confirmed as of 2023.

4. What are the primary risks affecting Edoxaban's market?
Patent expiration, competition from other oral anticoagulants, safety concerns related to bleeding, and regulatory shifts pose key risks.

5. Which regions will drive future growth of Edoxaban Tosylate?
Emerging markets in Asia-Pacific and Latin America are expected to contribute substantially to future revenue, supported by improving healthcare access and expanding indications.

References

[1] MarketWatch. (2022). Global Edoxaban Market Size, Share & Trends Analysis Report.
[2] Daiichi Sankyo. (2022). Annual Report 2022: Lixiana Sales Data.
[3] Global Data. (2022). Anticoagulants Market Forecast 2022-2027.
[4] U.S. Food and Drug Administration. (2015). Approval Letter for Savaysa.
[5] European Medicines Agency. (2021). Summary of Product Characteristics for Edoxaban.